The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase III study comparing EGFR tyrosine kinase inhibitor (EGFR-TKI) monotherapy and EGFR-TKI with inserted cisplatin (CDDP) plus pemetrexed (PEM) as a first-line treatment in patients (pts) with advanced non-squamous non–small-cell lung cancer (NSqNSCLC) harboring EGFR activating mutation (EGFR-NSqNSCLC): JCOG1404/WJOG8214L, AGAIN study.
 
Shintaro Kanda
Honoraria - AstraZeneca/Hong Kong; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo Pharmaceutical; Ono Pharmaceutical
 
Seiji Niho
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Janssen; Kyorin; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/UCB Japan
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); GlaxoSmithKline (Inst); Kyowa Kirin International (Inst); Lilly Japan (Inst); Nippon Kayaku (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Teijin Pharma (Inst); Teijin Pharma (Inst)
 
Takayasu Kurata
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD Oncology; Nippon Kayaku; Ono Pharmaceutical; Pfizer
Research Funding - Amgen; AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Shogo Nomura
Employment - Asahi Kasei (I)
Honoraria - AstraZeneca; Bayer; Chugai Pharma; Kyowa Hakko Bio
Research Funding - Amgen Astellas BioPharma (Inst); AstraZeneca (Inst)
 
Yosuke Kawashima
Honoraria - AstraZeneca/Hong Kong; Chugai Pharma; Kyowa Kirin; Life Technologies; Lilly Japan; Taiho Pharmaceutical
 
Yasuto Yoneshima
No Relationships to Disclose
 
Toshihide Yokoyama
Honoraria - AstraZeneca; Bristol-Myers Squibb Co. Ltd.; Chugai Pharma; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb Co. Ltd. (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Janssen (Inst); MSD K.K (Inst); PAREXEL International Inc. (Inst); Takeda (Inst)
 
Yasutaka Watanabe
No Relationships to Disclose
 
Hiroshi Tanaka
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Lilly; Merck KGaA; MSD; Nihonkayaku; Novartis; Ono Pharmaceutical; Pfizer; Sun Pharma; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; MSD Oncology
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Yutaka Fujiwara
Honoraria - Amgen; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly Japan; Merck; Nihonkayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chiome Bioscience; Daiichi Sankyo; MSD; Ono Pharmaceutical; Otsuka
Research Funding - Abbvie (Inst); Amgen (Inst); Anheart Therapeutics (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Incyte (Inst); Lilly Japan (Inst)
 
Yoshitaka Zenke
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD Oncology; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Merck Serono (Inst); MSD (Inst)
 
Koichi Azuma
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; MSD Oncology; Ono Pharmaceutical; Takeda
 
Hiroyuki Yamaguchi
No Relationships to Disclose
 
Ryo Toyozawa
Honoraria - AstraZeneca; Chugai Pharma; Lilly Japan; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); AnHeart Therapeutics (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst)
 
Yukio Hosomi
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Kirin International; Lilly Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Haruyasu Murakami
Honoraria - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; MSD; Nihonkayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Chugai Pharma; GAIA BioMedicine
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); IQvia (Inst); Takeda (Inst)
 
Satoshi Hara
No Relationships to Disclose
 
Akihiro Bessho
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); MSD K.K (Inst); Pfizer (Inst)
 
Nobuyuki Yamamoto
Honoraria - Amgen; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck; MSD; Novartis; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Takeda; Thermo Fisher Scientific
Research Funding - A2 Healthcare; Abbvie (Inst); Amgen; Amgen (Inst); Asahi Kasei (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Corporation; IQvia; Janssen (Inst); Lilly (Inst); Mebix; MSD (Inst); Novartis (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Yuichiro Ohe
Honoraria - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Celltrion; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Anheart Therapeutics; AstraZeneca; Celltrion; Chugai Pharma; Kyorin; Lilly Japan; Novartis; Ono Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Janssen (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)